An academic study of opioid-tracking data from the Drug Enforcement Administration revealed a significant drop in retail codeine sales in states with legal adult-use cannabis, but little impact on prescription opioid activity.
The study, published last week in the journal Health Economics, tracked a 26% reduction in retail pharmacy-based codeine distribution between 2010 and 2019 in nearly a dozen states that allow adults 21 and older to buy pot.
“This…
Market Watch
Read More
